2025.04.11
The Milecell team is thrilled to announce that our CEO, JINBAO ZHANG and our business development representative,, ZHONGYONG ZHENG will attend the 2025 AACR Annual Meeting in Chicago from April 25–30. As one of the largest gatherings in cancer research, AACR brings together over 20,000 global experts, innovators, and industry pioneers. This year’s event holds special significance, with 111 Chinese biopharma companies showcasing 246 innovative oncology assets, including 86 ADC candidates. Against this backdrop of scientific momentum, we aim to explore groundbreaking collaborations and advance transformative solutions for the industry.
Let’s Connect!
If you’re attending AACR 2025, we invite you to meet with Milecell’s team at the McCormick Place Convention Center. Together, we can unlock the potential of next-generation therapies and shape a healthier future.
Reach out via email: info@milecell-bio.com or our official website: www.milecell-bio.com. Let’s collaborate to empower biopharma innovation!
About Milecell Bio:
Founded in 2014, MileCell Biotechnology is a high-tech enterprise dedicated to high-quality human & animal primary cell solutions, providing products & CRO services to pharmaceutical companies and research laboratories, support preclinical research, clinical studies from Phase I to Phase III, and commercialization.
We specialize in：
lHuman Peripheral blood apheresis collection & Human/Animal immune cells isolation/purification services, eg. high-quality PBMCs and other immune cell subsets, including T cells, B cells, NK cells,Monocytes, CD34+ cells and many other cell types;
lIn vitro hepatic modeling solutions, including Animal hepatocytes, Non-parenchymal cells (NPCs) and Subcellular fractions;
lMedia/Reagents/Kits for cell culture needs:
-Cell Culture Media (Specialty & Supplement varieties). Each product is designed for optimal nutrition and growth of primary cells.
-Kryogene™ Cell Freezing Media-CGT (DMF# 040563), a highly efficient, safe, and easy-to-use serum-free cryopreservation media optimized for the special requirements of a variety of cell and gene therapy drugs (CAR-T, CAR-NK, MSC, iPSC, etc).
Our Mission & Vision
ØMission: Deliver Integrated Solutions Based on Primary Cells
ØVision: Drive Pharmaceutical Innovation for a Healthier Future
